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Sunitinib, an orally available receptor tyrosine kinase inhibitor, induces monocytic 
differentiation of acute myeogenouse leukemia cells that is enhanced by 
1,25-dihydroxyviatmin D3. 
To the Editor: Sunitinib, an orally available multitargeted receptor tyrosine kinases 
(RTK) inhibitor, effectively induced growth arrest and apoptosis of acute myelogenous 
leukemia (AML) cells with gain of function mutation in fms-like tyrosine kinase 3 
(FLT3) (FLT3-ITD) in vitro and in vivo.1 This study fount that sunitinib induced 
monocytic differentiation of AML cells irrespective of FLT3 gene status. For example, 
exposure of HL60 cells with the wild-type FLT3 as well as MOLM13 cells expressing 
FLT3-ITD to sunitinib increased levels of CD11b antigen, a marker of myeloid 
differentiation, on their cell surface (Figs 1A). Sunitinib also increased levels of CD14 
cell surface antigens and stimulated their endocytic capacity, as measured by 
internalization of FITC-labeled dextran (data not shown). Moreover, sunitinib 
stimulated production of inflammatory cytokines, such as interferon-γ (IFN-γ) and 
tumor necrosis factor-α (TNF-α) in AML cells (Figs 1B,C), indicating monocytic 
differentiation of AML cells. Sunitinib-mediated monocytic differentiation was further 
confirmed by morphological change (D). Interestingly, sunitinib-induced differentiation 
was significantly potentiated in the presence of 1,25(OH)2D3, a known inducer of 
monocytic differentiation in leukemia cells (Figs 1A-C).2 Furthermore, 1,25(OH)2D3 
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potentiated the ability of sunitinib to inhibit the clonogenic growth of AML cells (Figs 
1E). 
CCAAT/enhancer binding protein α (C/EBPα) belongs to a family of nuclear 
transcription factor and is required for myeloid differentiation.3 Sunitinib increased 
levels of C/EBPα in association with downregulation of c-Myc, a negative regulator of 
differentiation, in MOLM13 and HL60 cells (Fig 2). Sunitinib might induce monocytic 
differentiation of AML cells via modulation of these transcription factors.  
We next examine whether sunitinib affected activity of normal hematopoietic 
cells in vivo. Treatment of C57BL/6 mice (n=5) with sunitinib (20 mg/kg, 5 days) 
significantly increased population of CD14+ mononuclear cells and CD8+ T cells in 
their spleen as well as bone marrow (Table 1). Also, sunitinib stimulated production of 
IFN-γ  and TNF-α in their spleen mononuclear cells (Fig 3). These observations 
suggested that sunitinib activated the inflammatory cells in vivo.  
Finally, we attempted to verify the molecular mechanisms by which sunitinib 
induced monocytic differentiation of hematopoietic cells. Notable, when AML cells 
were pre-incubated with anti-human TNF-α monoclonal antibody infliximab (100 
ng/ml), sunitinib-induced expression of CD11b was almost completely blocked (Table 
2), suggesting the involvement of TNF-α-mediated signaling in sunitinib-inducing 
monocytic differentiation of AML cells. This study utilized the very low concentrations 
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of sunitinib (2.5-20 nM), which was not able to dephosphorylate FLT3 and its 
downstream signal pathways in MOLM13 and HL60 cells (data not shown). Sunitinib 
also induced the differentiation of U937 cells which did not express FLT3 on their cell 
surface (data not shown). Thus, sunitinib-induced differentiation was probably 
independent of FLT3. Recently, erlotinib as well as gefitinib, an inhibitor of the 
epidermal growth factor receptor (EGFR), induced growth arrest and differentiation of 
AML cells in vitro and in vivo, which was independent of EGFR signaling.4,5 Erlotinib 
and gefitinib could produce TNF-α, resulting in differentiation of AML cells. 
Taken together, sunitinib induced monocytic differentiation of AML cells 
irrespective of the FLT3 gene status. Clinical studies with this class of agents should 
include the individuals with AML expressing the wild-type FLT3.  
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Figure Legend 
Fig 1. Effects of 1,25(OH)2D3 on sunitinib-induced differentiation and growth 
arrest of AML cells. (A) MOLM13 and HL60 cells were cultured with either sunitinib 
(2.5-20 nM) and/or 1,25(OH)2D3 (0.005-0.5 μM). After 2 days, CD11b expressing 
population was measured by FACS. Results represent the mean ± SD of three 
experiments performed twice in duplicate plate. The statistical significance of difference 
was determined by one-way ANOVA followed by Boneferroni’s multiple comparison 
tests. *, p< 0.01, with respect to control cells treated with either sunitinib or 
1,25(OH)2D3 alone. VitD, 1,25(OH)2D3. Effects of 1,25(OH)2D3 and/or sunitinib on 
macrophage-related cytokines. (B, C) MOLM13 and HL60 cells were cultured with 
either sunitinib (2.5-20 nM) and/or 1,25(OH)2D3 (0.01-0.5μM). After 2 days, RNA was 
extracted and cDNAs were synthesized and subjected to real-time RT-PCR to measure 
the levels of (B) IFN-γ and (C) TNF-α. Results represent mean ± SD of triplicate 
cultures. The statistical significance of difference between cytokine production induced 
by either 1,25(OH)2D3 and/or sunitinib was determined by one-way ANOVA followed 
by Boneferroni’s multiple comparison tests. *, p<0.01. VitD, 1,25(OH)2D3. (D) 
May-Giemsa stain. MOLM13 cells were culture by replacing culture media containing 
sunitinib (2.5 μM) or control diluent (DMSO) every another day. After 8 days, cells 
were harvested and cytospin preparations were stained with May-Giemsa. Their 
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morphology was assessed under a light microscope. Original magnifications were x 
400. 1,25(OH)2D3 potentiated anti-proliferative effect of sunitinib. (E) Colony 
forming assay. MOLM13 and HL60 cells were cloned in soft agar and cultured with 
sunitinib (2.5-20 nM) or 1,25(OH)2D3 (1.25-50 nM) either alone or in combination. 
After 10 days, colonies were counted. Results are expressed as a mean percentage of 
control plates containing diluent. The statistical significance of difference between 
growth inhibition produced by either sunitinib or 1,25(OH)2D3 alone and those resulting 
from the combination of both was determined by one-way ANOVA followed by 
Boneferroni’s multiple comparison tests. Results represent the mean ± SD of 3 
experiments performed in triplicate. *, p<0.01. VitD, 1,25(OH)2D3. 
Fig 2. Effects of sunitinib on differentiation-related molecules. Western blot 
analysis. MOLM13 and HL60 cells were cultured with sunitinib (5-20 nM). After 2 
days, cells were harvested and subjected to Western blot analysis to monitor the levels 
of C/EBPα and c-Myc. Each lane was loaded with 30 μg of nuclear proteins. Levels of 
GAPDH were measured as a loading control.  
Fig 3. Effects of sunibinit on macrophage-related cytokines in vivo. Either sunitinib 
(n=5, 20 mg/kg) or control diluent (n=5) was administered to C57BL/6 mice by gavage 
for 5 days. At the end of the experiments, spleen was removed  and RNA was extracted. 
cDNAs were synthesized and subjected to real-time RT-PCR to measure the levels of 
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IFN-γ and TNF-α. Results represent mean ± SD of triplicate cultures. *, p<0.05; **, 
p<0.01.  
b 
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Table 1. CD14 and CD11b expression. 
                                                    
            CD14               CD8                   
control spleen      i15.5±1.9%          i35.5±2.9%   
sunitinib spleen     22.3±6.1%**        i39.6±2.6%**      
control BM          42.3±1.1%          i10.6±3.8% 
sunitinib BM        i47.0±3.6%**        i22.4±2.3%*       
 
Mice were treated with either sunitinib (20 mg/kg/day, for 5 days) or control diluent by 
gavage. At the end of experiments, mice were sacrificed, and spleen and BM were 
removed. Population of CD14- or CD8-expressing cells was quantified by FACS.  
* p<0.01, ** p<0.05. BM; bone marrow 
  
Table 2. Expression of CD11b. 
                                                    
              control        infliximab 100 ng/ml                   
MOLM13 
control            I o4.3 ± 1.9%         3.4 ± 0.5%   
sunitinib 2.5nM     I ¥25.6 ± 2.0%       I 3.5 ± 0.3%      
sunitinib 5 nM        39.8 ± 3.3%       I 4.5 ± 0.6% 
HL60                
control              4.1 ± 1.7 %        Ii0.8 ± 0.04% 
sunitinib 10 nM       29.2 ± 6.5 %        3.4 ± 0.3% 
sunitinib 20 nM       42.3 ± 3.2 %        5.8 ± 0.2%       
AML cells were pre-incubated with anti-human TNF-α monoclonal antibody infliximab 
(100 ng/ml) for 1 hr, and then exposed to various concentrations of sunitinib (2.5-20 
nM). After 2 days, cells were harvested, and CD11b expressing population was analyzed 
by flow cytometry.  
